PIPELINE
Our Key Asset
Elocalcitol
Elocalcitol
-
A high affinity orally available Vitamin D receptor (VDR) agonist.
-
A clinical stage Vitamin D analog with best-in-class safety profile established in several Phase 1 and Phase 2 trials
-
Elocalcitol belongs to same vitamin D analogue class as Eldecalcitol (Edirol®; Chugai) an approved osteoporosis drug in Japan
-
Elocalcitol has been shown to reduce the incidence of hypercalcemia by more than 100 times compared to Edirol®.
-
It is the only drug that increases bone formation and reduces bone resorption at the same time, so it is closely related to solving the pathogenesis of various rare diseases, including osteogenesis imperfecta, a bone disease.
-
Reversing hyperactive NF-κB signaling, recent studies have shown that NF-κB inhibition is effective in several neurological indications.It has been proven to reverse disease pathology.
-
Considering its mechanism of action (MOA) and expected therapeutic efficacy based on preclinical trial results, it may provide a safe treatment paradigm to clinically address several neurological disorders for which other treatments are lacking.
